This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ALISO VIEJO, Calif.,
March 20, 2014 /PRNewswire/ --
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects
in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the potential involvement of sigma-1 receptors. A link to the online article can be accessed at
"The study is the first to show that dextromethorphan has antidepressant-like effects in an
in vivo model and provides evidence that this effect occurs at least in part through a sigma-1 receptor dependent mechanism," said
Joao Siffert, MD, chief medical officer of Avanir. "Together with preliminary clinical observations, and based on dextromethorphan modulatory effects on glutamate and monoamine pathways, these data support our belief that dextromethorphan should be further explored as an antidepressant drug and we look forward to initiating a phase II clinical development program with our investigational drug AVP-786 in treatment resistant depression later this year."